**Background of CELA3A Antibody**
CELA3A (Chymotrypsin-Like Elastase Family Member 3A) is a proteolytic enzyme primarily synthesized in the pancreas as an inactive zymogen (pro-CELA3A). It belongs to the elastase family of serine proteases, which play critical roles in digesting dietary proteins by cleaving peptide bonds. CELA3A is activated in the small intestine via trypsin-mediated cleavage, contributing to nutrient breakdown and enzyme activation cascades.
CELA3A antibodies are immunological tools designed to detect and quantify CELA3A protein expression in research or diagnostic settings. These antibodies are pivotal in studying pancreatic physiology, digestive disorders (e.g., pancreatitis), and pathologies linked to dysregulated protease activity, such as certain cancers or inflammatory conditions. Monoclonal and polyclonal CELA3A antibodies are commercially available, often validated for techniques like Western blotting, immunohistochemistry, and ELISA.
Recent studies highlight CELA3A's potential as a biomarker in pancreatic diseases, including diabetes and pancreatic ductal adenocarcinoma. However, cross-reactivity with homologous elastases (e.g., CELA3B) requires careful validation to ensure specificity. Advances in recombinant protein technology have improved antibody production, enhancing their reliability in both basic research and clinical applications.